Pro Medicus, Ltd.

As of June 30, 2026, Pro Medicus, Ltd. carries a market capitalization of 12.54B, placing it among publicly traded companies globally. Its enterprise value stands at 12.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Pro Medicus, Ltd.'s next confirmed earnings release is scheduled for February 16, 2027.

As of June 30, 2026, Pro Medicus, Ltd. has 104.47M shares outstanding.

As of June 30, 2026, Pro Medicus, Ltd. trades at a trailing price-to-earnings ratio of 78.00. The price-to-sales ratio is 79.11, and the price-to-book ratio stands at 45.90.

As of June 30, 2026, Pro Medicus, Ltd. trades at an EV/EBITDA multiple of 100.18 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 78.16 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 104.30 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 12.39B versus a market cap of 12.54B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Pro Medicus, Ltd. maintains a current ratio of 6.85, meaning it holds 6.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Pro Medicus, Ltd. posted a return on equity (ROE) of 74.97, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 38.07 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 55.93, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 74.50, useful for judging operating efficiency across full business cycles. The company generates approximately 1.04M in revenue per employee across its workforce of 153.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Pro Medicus, Ltd. recorded 67.95M in income tax expense. That works out to an effective tax rate of 29.71, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 228.68M, leaving 160.73M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 4, 2026, Pro Medicus, Ltd.'s stock has declined approximately 35.83% over the past 52 weeks. The 50-day moving average sits at 111.03, while the 200-day moving average is 100.25.

Over the twelve months ended June 30, 2026, Pro Medicus, Ltd. generated 158.47M in revenue and converted that into 160.73M in net income, yielding earnings per share of 1.54. EBITDA reached 123.64M, while operating income came in at 118.75M.

As of June 30, 2026, Pro Medicus, Ltd. holds 151.81M in cash and equivalents against 1.35M in total debt, resulting in a net debt position of -130.92M. Total book value stands at 273.14M, with working capital of 185.19M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Pro Medicus, Ltd. posted a gross margin of 99.85, reflecting its pricing power and cost economics. The operating margin of 74.94 and net profit margin of 101.42 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Pro Medicus, Ltd. paid dividends of 0.38 per share. The dividend payout ratio of 24.41 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 0.37, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pro Medicus, Ltd. shareholders.

As of June 30, 2026, Pro Medicus, Ltd. has an Altman Z-Score of 81.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.